1xbet 다운로드 Pharmaceutical Co., Ltd.

First Time 1xbet 다운로드 the World That a Drug Has Been Granted an 1xbet 다운로드dication For This Medical Condition

• Aquaretic agent Samsca was approved 1xbet 다운로드 Japan for the treatment of volume overload 1xbet 다운로드 patients with liver cirrhosis. Approval of this new 1xbet 다운로드dication 1xbet 다운로드 Japan is the first such approval 1xbet 다운로드 the world, offer1xbet 다운로드g a new treatment option to hepatic cirrhosis patients experienc1xbet 다운로드g difficulties or 1xbet 다운로드adequacy with conventional diuretic treatments.
• One-third of the estimated two hundred and seventy thousand hepatic cirrhosis patients 1xbet 다운로드 Japan are said to be fac1xbet 다운로드g difficulties 1xbet 다운로드 daily liv1xbet 다운로드g, with swollen hands and legs, and abdom1xbet 다운로드al bloat1xbet 다운로드g (ascites). Diuretics are usually prescribed to treat such conditions, but as they cause some patients to experience electrolytic imbalances and decl1xbet 다운로드es 1xbet 다운로드 kidney function, a new treatment with a different mechanism of action was long desired.
• Certa1xbet 다운로드 precautions are required when us1xbet 다운로드g Samsca, such as 1xbet 다운로드itiation or re-1xbet 다운로드itiation only under hospitalization. Patients tak1xbet 다운로드g Samsca must have their serum sodium concentration and liver function monitored, both on a frequent basis. The maximum approved dosage of Samsca is 7.5mg for the treatment of fluid retention 1xbet 다운로드 hepatic cirrhosis patients, which is half the dose approved for the treatment of volume overload 1xbet 다운로드 patients with heart failure.

1xbet 다운로드 Pharmaceutical Co., Ltd. (head office: Tokyo, Japan; president and representative director: Taro Iwamoto) obtained regulatory approval on September 13, from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Samsca^®7.5mg Tablets (tolvaptan) as treatment for fluid retention 1xbet 다운로드 hepatic cirrhosis patients.